亚斯鲁化物通过促进AMPK/mTOR通路介导的自,缓解环胺诱导的骨髓抑制
Hong Che1, Linlin Li1, Bingjie Zhao1
1Department of Hematology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Journal of biochemical and molecular toxicology
|February 13, 2024
概括
阿斯鲁化物 (ASP) 通过通过AMPK/mTOR途径增强自性来缓解化疗诱导的骨髓抑制. 这项研究表明,ASP改善了用环胺 (CTX) 治疗的小鼠的血细胞计数和骨髓健康.
科学领域:
- 药理学 药理学是指药理学的学科.
- 在瘤学瘤学.
- 细胞生物学 细胞生物学
背景情况:
- 环胺 (CTX) 是一种广泛使用的化疗剂.
- 骨髓抑制是CTX治疗的重要和常见的不良影响.
- 赫迪奥蒂斯 (Hedyotis diffusa Willd.) 是一个散的植物. 含有阿斯鲁化物 (ASP),是一种潜在的治疗化合物.
研究的目的:
- 调查ASP在缓解CTX诱导的骨髓抑制中的有效性.
- 阐明ASP作用的潜在分子机制,重点关注自和AMPK/mTOR通路.
主要方法:
- 雄性C57BL/6小鼠接受了CTX和不同剂量的ASP或GM-CSF.
- 评估的体重,造血原生细胞计数 (CFU) 和血细胞指标.
- 分析了骨髓形态 (H&E),C-kit表达 (IHC),自标志物 (Beclin1,LC-3II/I) 和AMPK/mTOR通路蛋白质 (IHC,WB).
- 使用AMPK抑制剂 (dorsomorphin) 来确认途径的参与.
主要成果:
- 在接受CTX治疗的小鼠中,ASP治疗显著改善了体重和造血原生细胞数量.
- ASP增加了白细胞,红细胞和血小板的数量,以及GM-CSF,血小板蛋白和红细胞蛋白水平.
- ASP增强了CTX诱导的自 (Beclin1,LC-3II/I) 并调节了AMPK/mTOR通路.
- 用dorsomorphin抑制AMPK可以逆转ASP对骨髓抑制和自的保护作用.
结论:
- 阿斯普鲁索 (ASP) 有效地缓解了循环胺 (CTX) 诱导的骨髓抑制.
- 通过激活AMPK/mTOR信号通路,ASP通过促进自来发挥其保护作用.
- 这些发现表明ASP作为一种潜在的治疗剂来管理化疗诱导的副作用.
相关概念视频
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K
Allosteric Proteins-ATCase
5.7K
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
5.7K
Drugs that Destabilize Microtubules
2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K


